Featured Insight
Access90: Inflation Reduction Act Insights Series – Patient Affordability: A Key Question Answered
Will the Inflation Reduction Act actually increase drug affordability? Well…it’s complicated. RyanCox, VP, Director, PRECISIONvalue Access Experience Team, outlines the ways it will cut costs—and some watchouts. Learn more in this 90-second video.
Access90: Inflation Reduction Act Insights Series – Impacts on Competition A Key Question Answered
How do you compete against a negotiated drug? As the Inflation Reduction Act challenges current formulary dynamics, PRECISIONvalue expert Erin Lopata has a succinct answer: Prove your value. Learn more in this 90-second video.
Access90: Inflation Reduction Act Insight Series – Payer Controls: Question Two: How Could Manufacturers Adapt Their Approach to Patient Access?
Higher premiums. Increased brand exclusions. Limited treatment populations. Payers may deploy an arsenal of defenses against rising drug costs—and manufacturers should adapt to support patient access. Dominic Galante, Chief Medical Officer PRECISIONvalue, shares thoughts on effective strategies in this short Access90 video.
Access90: Inflation Reduction Act Insights Series – Patient Affordability: A Key Question Answered
Will the Inflation Reduction Act actually increase drug affordability? Well…it’s complicated. RyanCox, VP, Director, PRECISIONvalue Access Experience Team, outlines the ways it will cut costs—and some watchouts. Learn more in this 90-second video.
Access90: Inflation Reduction Act Insights Series – Impacts on Competition A Key Question Answered
How do you compete against a negotiated drug? As the Inflation Reduction Act challenges current formulary dynamics, PRECISIONvalue expert Erin Lopata has a succinct answer: Prove your value. Learn more in this 90-second video.
Access90: Inflation Reduction Act Insight Series – Payer Controls: Question Two: How Could Manufacturers Adapt Their Approach to Patient Access?
Higher premiums. Increased brand exclusions. Limited treatment populations. Payers may deploy an arsenal of defenses against rising drug costs—and manufacturers should adapt to support patient access. Dominic Galante, Chief Medical Officer PRECISIONvalue, shares thoughts on effective strategies in this short Access90 video.
On-Demand Webinar – SDOH and EHR – How are EHR vendors enabling providers’ efforts to close care gaps attributable to SDOH?
In this 1 hour live webinar, Precision experts Thad Nowakowski, Tim Van Aken, and Maureen Hennessey discuss the role that Social Determinants of Health plays in contributing to care gaps, current or proposed quality measures to support health equity, and how the top EHR vendors are enabling end user’s efforts to both capture SDOH variables, and act upon them to close care gaps.
On-Demand Webinar – Trends in Oncology: US Payer Management Considerations for 2022 and Beyond
In the last five years, 83 novel oncology substances have launched - oncology PMPM spend is now the highest among medical benefit categories, with 105% growth anticipated by 2024. As these numbers suggest, oncology is a key area of focus for payers, who are willing to invest resources to support appropriate utilization, but who struggle to keep up with the rapidly evolving science.
On-Demand Webinar – A Novel Data and Analytics-Informed Approach to Launch Excellence
Launching a therapy has become increasingly challenging, with only 34% of launches meeting their year-one goals (Evaluate Pharma, McKinsey). In addition, launches have also become more complex, with additional stakeholders to consider as well as the careful navigation of siloed, enterprise-wide functions and dynamic, fragmented data solutions. Not surprisingly, the path to a successful launch can be very narrow.
A Focus on the Inflation Reduction Act
Curious how the healthcare provisions in the Inflation Reduction Act will impact your business? Start with this booklet by key experts from PRECISIONvalue where 5 experts weigh in on how the Inflation Reduction Act will affect payers in addition to 2023 trends, events, and developments in the payer world. Download the booklet.
White Paper: Achieving Launch Excellence: A Novel Data- and Analytics-Informed Approach
Data and analytics can help drive and inform launch preparations and support efforts to achieve launch excellence through realistic goal-setting and risk mitigation. PRECISIONadvisors works with manufacturers, helping them make key decisions—related to product positioning, go-to-market strategy, and customer engagement across payers, providers, prescribers, and patients—through data- and analytics-driven insights. Learn how an integrated data-driven approach can set realistic goals and de-risk your launch.
White Paper: 2022 and Beyond: How Key Legislative Events Will Impact the Payer Landscape
Interested in learning more about several legislative events shaping the managed care landscape in 2022 and beyond? Check out this insightful white paper, based on our recent webinar, which features insights from PRECISIONvalue’s expert Access Experience Team on various legislative proposals and payers’ potential responses to regulatory changes.
Download Now: Precision October Events Calendar
The October Events Calendar is here! Get all the details on Precision at upcoming conferences, links to upcoming and on-demand webinars, and catch up on our latest thought leadership!
Download Now: Precision September Events Calendar
The October Events Calendar is here! Get all the details on Precision at upcoming conferences, links to upcoming and on-demand webinars, and catch up on our latest thought leadership!
Download Now: Precision June Events Calendar
The June Events Calendar is here! Stay up to date with all of the upcoming Precision conferences, on-demand events and recent thought leadership!
COVID-19 and Diabetes: Strategies to Catch Up
While new diagnoses of diabetes in adults have slowed in recent years, the pandemic may reverse this trend. Physicians, payers, and pharmaceutical companies all can play a part in mitigating the long-term effects on persons with diabetes. Precision's Cynthia Miller details how these stakeholders can collaborate to mitigate future damage.
On-Demand Webinar: Closing the Gaps in Diabetes Care: Emerging Tools and Approaches
In 2021, PRECISIONvalue launched a proprietary survey of the care management ecosystem (including payers and health systems) and found diabetes to be one of the top conditions for which individuals are referred for care management.
Upcoming Webinar: Forging Patient Connections: How Evidence-Based Technologies Are Expanding Access and Adherence
Join us on Thursday, 10/21 @ 1:00 PM ET for this engaging webinar with PQA Quality Forum, featuring PRECISIONvalue's Maureen Hennessey.
White Paper: Trends in 2021: Insights on Healthcare Costs, Innovation, Policy, Value-Based Care, and the Pandemic
In 2021, COVID-19 and its ongoing impact on the healthcare, scientific, political, and social climate continued to be the dominant transformative lens through which we view trends in the following areas: healthcare costs, clinical practice and scientific innovation, US healthcare policy, value-based care, and pandemic/endemic management.
Impact of NextGen Access Decision Makers on Health Care Services and Therapies
In the midst of the pandemic uncertainties, organizations are continuing their quest for value-based care. Precision's Elizabeth Oyekan and Dominic Galante discuss who will be the next generation access decision makers to successfully take the Triple Aim premise of value-based care, couple it with lessons learned from the pandemic, scale it up, and sustain success over time to make a palpable difference in the US healthcare system.
AMCP & Precision ADVANCE Corporate Training Program
Cell and gene therapies present tremendous clinical and humanistic opportunity to change the course of disease but also present several unique aspects that differ from more traditional therapies. These differences will impact how innovators develop evidence and manufacture and distribute products. Payers also need to adapt how they assess value, make coverage decisions, and manage reimbursement.
With 20 Biosimilars Available, U.S. Market Is Heating Up
In an October 2020 healthcare industry report, the authors projected that biosimilars could hit $80 billion in aggregate sales and provide savings in excess of $100 billion in aggregate over the next five years. Precision's Dan Danielson joins other industry experts to discuss the impact of biosimilars in 2020 and the forecast for the biosimilars landscape going forward.
Pharma Innovation Is Poised to Continue Beyond COVID Vaccines, Drugs This Year
While the COVID-19 pandemic seems likely to remain the dominant headline in 2021, a host of other potential occurrences could have big impacts this year. Precision's Dan Danielson joins a variety of industry experts to discuss what's ahead in 2021 for healthcare and pharma beyond the pandemic.
Payer Implications on Reforms to Price Transparency
Recent reforms on price transparency will substantially increase payers' workloads. The Trump administration and CMS recently released a final rule that will require payers to post documents that include in-network and out-of-network provider rates and in-network drug prices starting in 2022. And in 2023, private insurers will be required to provide negotiated provider cost-sharing estimates and up-front prices to members.
Healthcare Agency Roundtable
Leadership teams from the 2020 Manny Award winners and finalists participated in a comprehensive Q&A forum on a variety of healthcare industry themes and trends.
Precision Medicine Group Significantly Expands Cell and Gene Therapy Expertise with Acquisition of Project Farma
LEADING BIO-ENGINEERING AND MANUFACTURING SERVICES FIRM CATALYZES THE LAUNCH OF PRECISION’S CELL AND GENE THERAPY OFFERING—'PRECISION ADVANCE’—ADDRESSING THE UNIQUE CHALLENGES OF CELL & GENE THERAPY INNOVATORS, FROM DEVELOPMENT THROUGH COMMERCIALIZATION
NCCN Recommends Zanubrutinib as First-Line, Second-Line Therapy in CLL, SLL
The National Comprehensive Cancer Network (NCCN) recommended zanubrutinib, approved by the FDA for the treatment of adult patients with mantle cell lymphoma (MCL), for treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). The AJMC asked Precision's Erin Lopata to weigh in on how to respond when a drug is added to NCCN guidelines before the FDA approves the indication.
